What is Vialin used for?

Vialin is indicated for Hypotension Secondary to Spinal Anesthesia, Low blood pressure, Prevention of Hypotension During Spinal Anesthesia.

What development phase is Vialin in?

Vialin is FDA-approved (marketed).

What is the generic name of Vialin?

MEPHENTERMINE is the generic (nonproprietary) name of Vialin.

Last reviewed 2026-04-20 · How we verify

Vialin (MEPHENTERMINE)

Baxter · FDA-approved approved Small molecule Quality 35/100

Vialin, a mephentermine product marketed by Baxter, is indicated for hypotension secondary to spinal anesthesia and faces competition from several same-class drugs, including off-patent options like dopamine and dobutamine. Its mechanism of action through the alpha-1A adrenergic receptor provides a targeted approach to increasing blood pressure, distinguishing it in the treatment of perioperative hypotension. The primary risk to Vialin's market position is the presence of multiple generic competitors and the upcoming key composition patent expiry in 2028.

At a glance

Generic name	MEPHENTERMINE
Sponsor	Baxter
Drug class	Indirectly Acting Sympathomimetic Amines
Target	Alpha-1A adrenergic receptor
Modality	Small molecule
Therapeutic area	Hematology
Phase	FDA-approved
First approval	1951

Approved indications

Hypotension Secondary to Spinal Anesthesia
Low blood pressure
Prevention of Hypotension During Spinal Anesthesia

Common side effects

No common side effects on file.

Drug interactions

pargyline
phenelzine
tranylcypromine

Key clinical trials

Comparative Analytical Study of Intravenous Bolus Dose of Mephentermine and Phenylephrine for Hemodynamic Stability During Elective Cesarean Section Under Spinal Anesthesia at KIST Medical College and Teaching Hospital (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vialin CI brief — competitive landscape report
Vialin updates RSS · CI watch RSS
Baxter portfolio CI